Literature DB >> 17947512

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Ronald Vogels1, David Zuijdgeest, Michelle van Meerendonk, Arjen Companjen, Gert Gillissen, Jeroen Sijtsma, Irene Melis, Lennart Holterman, Katarina Radosevic, Jaap Goudsmit, Menzo J E Havenga.   

Abstract

Replication-incompetent adenovirus type 35 (rAd35) represents a potent vaccine carrier that elicits strong, antigen-specific T- and B-cell responses in diverse preclinical models. Moreover, Ad35 is rare in human populations, resulting in the absence of neutralizing antibodies against this carrier, in contrast to the commonly used rAd5. Therefore, rAd35 is being investigated as a vaccine carrier for a number of diseases for which an effective vaccine is needed, including malaria, AIDS and tuberculosis. However, it can be perceived that effective immunization will require insertion of multiple antigens into adenoviral vectors. We therefore wanted to create rAd35 vectors carrying double expression cassettes, to expand within one vector the number of insertion sites for foreign DNA encoding antigenic proteins. We show that it is possible to generate rAd35 vectors carrying two cytomegalovirus promoter-driven expression cassettes, provided that the polyadenylation signals in each expression cassette are not identical. We demonstrate excellent rAd35 vector stability and show that expression of a transgene is not influenced by the presence of a second expression cassette. Moreover, by using two model vaccine antigens, i.e. the human immunodeficiency virus-derived Env-gp120 protein and the Plasmodium falciparum-derived circumsporozoite protein, we demonstrate that potent T- and B-cell responses are induced to both antigens expressed from a single vector. Such rAd35 vectors thus expand the utility of rAd35 vaccine carriers for the development of vaccines against, for example, malaria, AIDS and tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947512     DOI: 10.1099/vir.0.83119-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

2.  Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Authors:  Thomas W Geisbert; Michael Bailey; Lisa Hensley; Clement Asiedu; Joan Geisbert; Daphne Stanley; Anna Honko; Joshua Johnson; Sabue Mulangu; Maria Grazia Pau; Jerome Custers; Jort Vellinga; Jenny Hendriks; Peter Jahrling; Mario Roederer; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

3.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

4.  Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.

Authors:  Nathaniel J Schuldt; Yasser A Aldhamen; Sarah Godbehere-Roosa; Sergey S Seregin; Youssef A Kousa; Andrea Amalfitano
Journal:  Malar J       Date:  2012-06-21       Impact factor: 2.979

Review 5.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Authors:  Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.